Adjuvant Pazopanib in Stage I NSCLC

Summary

The aim of this study is to evaluate the efficacy and safety of pazopanib compared with placebo in patients with T \< or = 5 cm, N0 (stage I according to TNM 2009) completely resected NSCLC.

Timeline

Start

2008-11

Primary completion

2015-12

Completion

2016-04-18

Outcome

Met primary endpoint

paper Pazopanib compliance was 38% [95% confidence interval (CI) 23-55] with P800, increasing to 69% (95% CI 50-84; P = 0.027) with P400. PMID 28327934 ↗

Publications

• Results Besse B, Mazieres J, Ribassin-Majed L, Barlesi F, Bennouna J, Gervais R, Moreau L, Berard H, Debieuvre D, Molinier O, Moro-Sibilot D, Souquet PJ, Jacquot S, Petit L, Lena H, Pignon JP, Lacas B, Morin F, Milleron B, Zalcman G, Soria JC; Intergroupe Francophone de Cancerologie Thoracique (IFCT). Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial. Ann Oncol. 2017 May 1;28(5):1078-1083. doi: 10.1093/annonc/mdx070.

Drugs

Indications